The incidence of colorectal cancers detected at an early stage, that is stage T2 or less, has increased over the last decade, driven primarily by better access to screening and diagnostic pathways. Consequently, timely treatment leads to better outcomes. Early stage rectal cancers (ERC), by virtue of their location, allows for alternative treatment strategies towards organ (rectum) preservation. Local excision techniques have evolved and improved with advances in radiological assessment and minimally invasive surgery. However, decisions on treatment to mitigate local recurrence remain a challenge. This chapter explores the current understanding of the management of ERC and offers insights to the multidisciplinary team to aid treatment strat...
Management of rectal cancer has markedly evolved over the last two decades. New technologies of stag...
Approximately one third of all colorectal malignancies are located in the rectum. It has long been r...
Colorectal cancer is the 3rd most common malignant disease worldwide and it represents the major pub...
The incidence of colorectal cancers detected at an early stage, that is stage T2 or less, has increa...
It is important to understand advances in treatment options for rectal cancer. We attempt to highlig...
The implementation of bowel cancer screening programs has led to a rise in the incidence of early re...
Early rectal cancer management includes tumour stages TiS, T1 and some selected T2 lesions that unde...
The last 30 years have witnessed a significant increase in the diagnosis of early-stage rectal cance...
Colorectal cancer (CRC) is one of the most common cancers in the world and is expected to rise from ...
Colorectal cancer (CRC) is one of the most commonly diagnosed cancer in Europe and US A and one of t...
The introduction of new technologies for diagnosis and screening programs led to an increasing rate ...
International audienceKnowledge of the biology and management of rectal cancer continues to improve....
Background: Rectal cancer is one of the frequent human malignant neoplasms and the second most commo...
Fortunately, locally recurrent rectal cancer (LRRC) has become a rare disease, despite the increase ...
Advancements in rectal cancer treatment have resulted in improvement only in locoregional control an...
Management of rectal cancer has markedly evolved over the last two decades. New technologies of stag...
Approximately one third of all colorectal malignancies are located in the rectum. It has long been r...
Colorectal cancer is the 3rd most common malignant disease worldwide and it represents the major pub...
The incidence of colorectal cancers detected at an early stage, that is stage T2 or less, has increa...
It is important to understand advances in treatment options for rectal cancer. We attempt to highlig...
The implementation of bowel cancer screening programs has led to a rise in the incidence of early re...
Early rectal cancer management includes tumour stages TiS, T1 and some selected T2 lesions that unde...
The last 30 years have witnessed a significant increase in the diagnosis of early-stage rectal cance...
Colorectal cancer (CRC) is one of the most common cancers in the world and is expected to rise from ...
Colorectal cancer (CRC) is one of the most commonly diagnosed cancer in Europe and US A and one of t...
The introduction of new technologies for diagnosis and screening programs led to an increasing rate ...
International audienceKnowledge of the biology and management of rectal cancer continues to improve....
Background: Rectal cancer is one of the frequent human malignant neoplasms and the second most commo...
Fortunately, locally recurrent rectal cancer (LRRC) has become a rare disease, despite the increase ...
Advancements in rectal cancer treatment have resulted in improvement only in locoregional control an...
Management of rectal cancer has markedly evolved over the last two decades. New technologies of stag...
Approximately one third of all colorectal malignancies are located in the rectum. It has long been r...
Colorectal cancer is the 3rd most common malignant disease worldwide and it represents the major pub...